NZ521270A - Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line - Google Patents

Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line

Info

Publication number
NZ521270A
NZ521270A NZ521270A NZ52127001A NZ521270A NZ 521270 A NZ521270 A NZ 521270A NZ 521270 A NZ521270 A NZ 521270A NZ 52127001 A NZ52127001 A NZ 52127001A NZ 521270 A NZ521270 A NZ 521270A
Authority
NZ
New Zealand
Prior art keywords
mva
cell line
vero
cells
vaccinia virus
Prior art date
Application number
NZ521270A
Other languages
English (en)
Inventor
Anton Mayr
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NZ521270A publication Critical patent/NZ521270A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ521270A 2000-03-14 2001-03-10 Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line NZ521270A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000410 2000-03-14
PCT/EP2001/002703 WO2001068820A1 (en) 2000-03-14 2001-03-10 Altered strain of the modified vaccinia virus ankara (mva)

Publications (1)

Publication Number Publication Date
NZ521270A true NZ521270A (en) 2003-06-30

Family

ID=8159327

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521270A NZ521270A (en) 2000-03-14 2001-03-10 Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line

Country Status (25)

Country Link
US (1) US6682743B2 (https=)
EP (1) EP1263936B1 (https=)
JP (1) JP4759201B2 (https=)
KR (1) KR100880765B1 (https=)
CN (1) CN1291012C (https=)
AT (1) ATE305030T1 (https=)
AU (1) AU780696B2 (https=)
BR (1) BR0109158A (https=)
CA (1) CA2397675C (https=)
CZ (1) CZ293690B6 (https=)
DE (1) DE60113512T2 (https=)
DK (1) DK1263936T3 (https=)
EE (1) EE05633B1 (https=)
ES (1) ES2249430T3 (https=)
HK (1) HK1052725B (https=)
HU (1) HU228691B1 (https=)
IL (3) IL150736A0 (https=)
MX (1) MXPA02008873A (https=)
NO (1) NO20024246L (https=)
NZ (1) NZ521270A (https=)
PL (1) PL205922B1 (https=)
RU (1) RU2280075C2 (https=)
SI (1) SI1263936T1 (https=)
UA (1) UA84388C2 (https=)
WO (1) WO2001068820A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
CN100540051C (zh) 2002-04-19 2009-09-16 巴法里安诺迪克有限公司 用于接种新生儿的改良的安卡拉痘苗病毒
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DK1536015T3 (da) * 2003-11-24 2008-02-18 Bavarian Nordic As Promotorer til ekspression i modificeret vacciniavirus Ankara
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7607323B1 (en) 2007-10-16 2009-10-27 Hall Charles F Curl resistant shirt collar and method of fabricating same
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
JP5798124B2 (ja) * 2009-11-20 2015-10-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015138471A1 (en) * 2014-03-10 2015-09-17 Arizona Board Of Regents On Behalf Of Arizona State University Heat inactivated poxvirus improves vaccination results
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
CN115300622A (zh) * 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
EP4519445A2 (en) * 2022-05-04 2025-03-12 University of Maryland, College Park Rna vectors with hairpin-like inserts
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2076735C1 (ru) * 1994-03-23 1997-04-10 ГНЦВБ "Вектор" Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DE69837493T2 (de) * 1997-10-15 2007-12-13 Asahi Kasei Pharma Corp. Verfahren zur qualitätssicherstellung von wässrigen parenteralen lösungen mit thrombomodulin in der lagerung und verteilung
JP3736622B2 (ja) * 2001-06-15 2006-01-18 セイコーエプソン株式会社 ライン駆動回路、電気光学装置及び表示装置

Also Published As

Publication number Publication date
EP1263936A1 (en) 2002-12-11
CA2397675A1 (en) 2001-09-20
KR100880765B1 (ko) 2009-02-02
HUP0300120A2 (en) 2003-05-28
US6682743B2 (en) 2004-01-27
CN1291012C (zh) 2006-12-20
HU228691B1 (en) 2013-05-28
CA2397675C (en) 2012-11-13
CN1418248A (zh) 2003-05-14
CZ293690B6 (cs) 2004-07-14
DK1263936T3 (da) 2006-02-13
RU2280075C2 (ru) 2006-07-20
EE05633B1 (et) 2013-02-15
WO2001068820A1 (en) 2001-09-20
ATE305030T1 (de) 2005-10-15
DE60113512T2 (de) 2006-06-22
AU780696B2 (en) 2005-04-14
BR0109158A (pt) 2003-04-22
HK1052725A1 (en) 2003-09-26
HUP0300120A3 (en) 2010-01-28
US20030013190A1 (en) 2003-01-16
JP4759201B2 (ja) 2011-08-31
PL357378A1 (en) 2004-07-26
DE60113512D1 (de) 2006-02-02
IL150736A (en) 2008-06-05
HK1052725B (zh) 2007-03-23
IL150736A0 (en) 2003-02-12
NO20024246D0 (no) 2002-09-05
IL188667A (en) 2011-09-27
ES2249430T3 (es) 2006-04-01
MXPA02008873A (es) 2003-02-10
IL188667A0 (en) 2008-04-13
NO20024246L (no) 2002-09-05
UA84388C2 (ru) 2008-10-27
EP1263936B1 (en) 2005-09-21
KR20030032928A (ko) 2003-04-26
SI1263936T1 (sl) 2006-06-30
PL205922B1 (pl) 2010-06-30
AU5826901A (en) 2001-09-24
EE200200507A (et) 2004-02-16
JP2003526362A (ja) 2003-09-09
RU2002124622A (ru) 2004-03-27

Similar Documents

Publication Publication Date Title
NZ521270A (en) Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
JP5154632B2 (ja) ウイルス増殖法
WO2021184560A1 (zh) 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
DK2295065T3 (da) Modificeret varmechockprotein-antigenpeptidkompleks
Zhao et al. Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicity
CN113845576A (zh) 重组猫疱疹病毒1型gB-gD蛋白及其应用
KR890014740A (ko) 재조합 마렉병 비루스 및 백신
ES8600059A1 (es) Procedimiento para la preparacion de un plasmido recombinante insertado con el gen del virus de la hepatitis b.
FR2602791B1 (fr) Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
CN102198268A (zh) 表达马链球菌兽疫亚种类m蛋白的重组猪痘病毒载体疫苗
CN105462937A (zh) 一种肠道病毒嵌合病毒样颗粒疫苗及其制备方法和应用
CN105541977A (zh) 鸭疫里默氏杆菌OmpH截段重组蛋白及制备方法与应用
CN102988969B (zh) 表达禽网状内皮组织增生病病毒gp90基因的DNA疫苗及其构建方法和应用
CN113583141B (zh) 猪流行性腹泻病毒Nsp9蛋白、含该Nsp9蛋白的融合蛋白及其制备方法和应用
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
CN118894910B (zh) 一种PRRSV-GP3-GP5-M+PCV2-TBCap重组蛋白、疫苗及应用
Tripathi et al. Development of a pilot-scale production process and characterization of a recombinant Japanese encephalitis virus envelope domain III protein expressed in Escherichia coli
NO20032097L (no) Gj¶ravledet vaksine mot IPNV
CN117050191B (zh) 一种具有抑制BPIV3以及BoHV-1感染作用的抗病毒融合肽及其应用
CN118256450A (zh) 一种2型兔出血症病毒毒株及其表达方法和应用
CN110386965B (zh) 一种坦布苏病毒e蛋白b细胞表位及其编码基因和应用
CN115737798B (zh) 鸭il-7作为佐剂在鸭坦布苏病毒灭活疫苗中的应用
CN107653254A (zh) 一种猪繁殖与呼吸综合症病毒重组orf5基因及其制备方法
WO2006062266A1 (en) Genes of a korean isolate rbiv and a vaccine against rbiv
CN105132437A (zh) 表达鼠伤寒沙门菌OmpL蛋白的重组猪痘病毒载体疫苗

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BAVARIAN NORDIC A/S, DK

Free format text: OLD OWNER(S): ANTON MAYR

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed